Owlstone Medical recruits first patient in phase 2 clinical trial for the early detection of lung cancer through breath biopsy

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced recruitment of the first patient into its EVOLUTION Phase 2 clinical trial following successful achievement of key safety and proof of concept milestones in Phase 1.

Immunic to Participate in Investor and Scientific Conferences in February – Biotech Investments

Issuer: Immunic AG / Key word(s): Conference 04.02.2025 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate

February 5, 2025

Orphelia explores avenues for liquid neuroblastoma med after EU CHMP rejection – Pharmaceutical Technology

Orphelia said it will continue to make Kizfizo available to paediatric patients under certain programmes and clinical trials. Credit: Andrii Yalanskyi via Getty Images. Orphelia

March 14, 2025

Drugmakers ‘not doing everything that they could’ to widen global access, new report finds

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.